Open AccessIn vitro activities of new macrolides and rifapentine against Brucella spp
Author(s) -
J.Á. García-Rodríguez,
Juan Luis Muñoz Bellido,
Marı́a José Fresnadillo,
I Trujillano
Publication year - 1993
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.37.4.911
Subject(s) - rifapentine , roxithromycin , clarithromycin , microbiology and biotechnology , azithromycin , moxifloxacin , streptomycin , antibacterial agent , aminoglycoside , erythromycin , in vitro , trimethoprim , antibiotics , biology , medicine , mycobacterium tuberculosis , tuberculosis , biochemistry , pathology , latent tuberculosis
We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram/ml).